Skip to main content
. 2014 Feb 10;32(9):927–934. doi: 10.1200/JCO.2013.51.1261

Fig 2.

Fig 2.

Unadjusted adjuvant trastuzumab completion rates (95% CIs) by (A) age and (B) comorbidity; (C) trastuzumab completion rates by age and comorbidity (comorbidity includes patients with 1 and 2+ comorbidities). Y-axes indicate age groups, left, and hazard ratios with CIs, right. Overall P values determined by χ2 testing.